The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -323,086 |
| Depreciation and amortization | 84,163 |
| Paid in-kind interest expense | 29,718 |
| Premium deficiency reserve | 18,749 |
| Amortization of original issue discount and debt issuance costs | 13,556 |
| Mark-to-market adjustment of stock warrants | -7,850 |
| Equity-based compensation | 5,581 |
| Provision for bad debts | 2,996 |
| Gain (loss) on disposition of property plant equipment, excluding oil and gas property and timber property | -162 |
| Impairment of assets held for sale | 0 |
| Gain on write off of contingent consideration | 0 |
| Deferred income taxes | 2,868 |
| Health plan receivable | -28,677 |
| Clinic fees, insurance, and other receivable | 2,297 |
| Prepaid expenses and other current assets | -2,983 |
| Other long-term assets | 3,525 |
| Accounts payable, accrued expenses, and other current liabilities | 11,108 |
| Accrued payroll | -772 |
| Health plan settlements payable | 14,265 |
| Claims payable | 32,701 |
| Accrued interest | -1,876 |
| Other long-term liabilities | 0 |
| Operating lease liability | 641 |
| Net cash used in operating activities | -91,238 |
| Purchases of property and equipment | -79 |
| Proceeds from asset sale | 50 |
| Net cash provided by investing activities | 129 |
| Proceeds from long-term debt, net of original issue discount | 73,000 |
| Payment of debt issuance costs | 186 |
| Proceeds from liability-classified warrants and private placement offering, net of offering costs paid | 0 |
| Proceeds from at-the-market sales, net of offering costs paid | 0 |
| Deferred offering costs paid | 0 |
| Payment of tax withholdings upon settlement of restricted stock unit awards | 0 |
| Repayment of short-term and long-term debt | 1,137 |
| Proceeds from short-term debt | 1,137 |
| Net cash provided by financing activities | 72,814 |
| Net change in cash and restricted cash | -18,295 |
| Cash and restricted cash, beginning of year | 44,102 |
| Cash and restricted cash, end of year | 25,807 |
P3 Health Partners Inc. (PIII)
P3 Health Partners Inc. (PIII)